Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
Phase II Trial of Sparing the Urethra, Pudendal Artery and Rectum During Stereotactic Ablative Body Radiotherapy (SUPR-SABR) for Favorable and Intermediate Risk Prostate Cancer
NCT Number:
NCT05668351
Phase:
II
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Prostate
Study Objectives:
To evaluate the 12-month patient reported GU and GI toxicity of SUPR- SABR.1. To further evaluate the toxicity profile of SUPR-SABR based on: 24-month Expanded Prostate Cancer Index Composite (EPIC) urinary and bowel domain scores (patient reported), Incidence of CTCAE grade 3 or higher safety events (physician reported), 1-month GU toxicity
Study Documents
(MUSC NetID required for document access)